Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

727 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Detection of multiple druggable mutations of lung cancer from cytology specimens by MINtS: An advanced medicine A trial.
Fujita K, Arai R, Shoji S, Saito R, Nomura M, Hotta T, Asahina H, Kawakami M, Nakachi I, Hasegawa Y, Okafuji K, Suzuki A, Miyanaga A, Sunaga N, Nagashima H, Ikeda N, Watanabe S, Nagai Y, Furuta M, Kage H, Arai D, Fukuhara T, Nakayama M, Morita S, Kobayashi K, Hagiwara K. Fujita K, et al. Among authors: furuta m. Cancer Sci. 2023 Aug;114(8):3342-3351. doi: 10.1111/cas.15831. Epub 2023 May 3. Cancer Sci. 2023. PMID: 37139543 Free PMC article.
A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002).
Ikezawa Y, Asahina H, Oizumi S, Watanabe M, Takamura K, Kawai Y, Yamada N, Harada T, Kinoshita I, Fujita Y, Miyauchi E, Ogi T, Amano T, Furuta M, Sakakibara-Konishi J, Nishihara H, Dosaka-Akita H, Isobe H, Nishimura M; Hokkaido Lung Cancer Clinical Study Group. Ikezawa Y, et al. Among authors: furuta m. Cancer Chemother Pharmacol. 2017 Nov;80(5):955-963. doi: 10.1007/s00280-017-3432-4. Epub 2017 Sep 13. Cancer Chemother Pharmacol. 2017. PMID: 28905108 Free article. Clinical Trial.
Current status of first-line treatment with pembrolizumab for non-small-cell lung cancer with high PD-L1 expression.
Ikezawa Y, Mizugaki H, Morita R, Tateishi K, Yokoo K, Sumi T, Kikuchi H, Kitamura Y, Nakamura A, Kobayashi M, Aso M, Kimura N, Yoshiike F, Furuta M, Tanaka H, Sekikawa M, Hachiya T, Nakamura K, Shimokawa M, Oizumi S. Ikezawa Y, et al. Among authors: furuta m. Cancer Sci. 2022 Jun;113(6):2109-2117. doi: 10.1111/cas.15361. Epub 2022 Apr 15. Cancer Sci. 2022. PMID: 35377496 Free PMC article.
Successful Application of Edoxaban in the Treatment of Venous Thromboembolism Recurrence in a Patient with Non-small Cell Lung Cancer after Tumor Shrinkage.
Shoji T, Mizugaki H, Ikezawa Y, Furuta M, Takashima Y, Kikuchi H, Goudarzi H, Asahina H, Kikuchi J, Kikuchi E, Sakakibara-Konishi J, Shinagawa N, Tsujino I, Nishimura M. Shoji T, et al. Among authors: furuta m. Intern Med. 2018 Jun 15;57(12):1769-1772. doi: 10.2169/internalmedicine.9741-17. Epub 2018 Feb 9. Intern Med. 2018. PMID: 29434159 Free PMC article.
Risk of bleeding associated with transbronchial biopsy using flexible bronchoscopy in patients with echocardiographic or chest CT evidence of pulmonary hypertension.
Takashima Y, Shinagawa N, Morinaga D, Nakamura J, Furuta M, Shoji T, Asahina H, Kikuchi E, Kikuchi J, Sakakibara-Konishi J, Tsujino I, Konno S. Takashima Y, et al. Among authors: furuta m. BMC Pulm Med. 2022 Nov 28;22(1):449. doi: 10.1186/s12890-022-02245-y. BMC Pulm Med. 2022. PMID: 36443763 Free PMC article.
Evaluating the immunoproteasome as a potential therapeutic target in cisplatin-resistant small cell and non-small cell lung cancer.
Shoji T, Kikuchi E, Kikuchi J, Takashima Y, Furuta M, Takahashi H, Tsuji K, Maeda M, Kinoshita I, Dosaka-Akita H, Sakakibara-Konishi J, Konno S. Shoji T, et al. Among authors: furuta m. Cancer Chemother Pharmacol. 2020 May;85(5):843-853. doi: 10.1007/s00280-020-04061-9. Epub 2020 Mar 30. Cancer Chemother Pharmacol. 2020. PMID: 32232513 Free article.
Bromodomain and extraterminal domain inhibition synergizes with WEE1-inhibitor AZD1775 effect by impairing nonhomologous end joining and enhancing DNA damage in nonsmall cell lung cancer.
Takashima Y, Kikuchi E, Kikuchi J, Suzuki M, Kikuchi H, Maeda M, Shoji T, Furuta M, Kinoshita I, Dosaka-Akita H, Sakakibara-Konishi J, Konno S. Takashima Y, et al. Among authors: furuta m. Int J Cancer. 2020 Feb 15;146(4):1114-1124. doi: 10.1002/ijc.32515. Epub 2019 Jun 28. Int J Cancer. 2020. PMID: 31199520 Free article.
Numb has distinct function in lung adenocarcinoma and squamous cell carcinoma.
Kikuchi H, Sakakibara-Konishi J, Furuta M, Kikuchi E, Kikuchi J, Oizumi S, Hida Y, Kaga K, Kinoshita I, Dosaka-Akita H, Nishimura M. Kikuchi H, et al. Among authors: furuta m. Oncotarget. 2018 Jun 29;9(50):29379-29391. doi: 10.18632/oncotarget.25585. eCollection 2018 Jun 29. Oncotarget. 2018. PMID: 30034624 Free PMC article.
727 results